Research and Development (R&D) Contract Agreement

Description

Research and Development (R&D) Contract Agreement

1. SCOPE OF SERVICES

   1.1. Project Foundation: The Manufacturer shall provide professional Research and Development (R&D) services to create a customized formulation based strictly on the specifications outlined in the “Product Development Summary” (or Product Brief) submitted by the Brand Owner. This document serves as the primary technical blueprint for the project.
   1.2. Discovery and Design: The Manufacturer will conduct a discovery phase to establish the product’s core identity, including its specific type (e.g., serum, lotion, soap), desired viscosity/texture, sensory profile (scent and skin-feel), and functional active benefits.
   1.3. Use of Benchmarks: To ensure accuracy and minimize development time, the Brand Owner is encouraged to provide a physical “Benchmark Product.” This benchmark serves as a target reference for aesthetics, performance, and fragrance. The Manufacturer will use its expertise to replicate or improve upon this benchmark within the limits of the agreed-upon cost and ingredient constraints.
   1.4. Formulation Trials and Revisions: The standard R&D fee covers the labor and materials for two (2) distinct formulation trials:Trial 1 (Initial Batch): The first physical prototype based on the initial brief and benchmarks.
   Trial 2 (Revision Batch): One round of adjustments based on the Brand Owner’s feedback from Trial 1 (e.g., slight changes to scent intensity, color, or thickness).Additional Trials: Any requests for revisions beyond Trial 2 (Trial 3 onwards) or significant changes to the original product brief will be considered a new R&D project and may be subject to additional fees.
2. FEES AND TIMELINES
   2.1 Development Fee: The standard fee for customized formulation is between Php 6,000.00 to Php 9,500.00.
   2.2 Standard Lead Time: The development of the initial sample batch typically takes 2 to 4 weeks.
   2.3 Elaborated Timeline & Delays: Both parties acknowledge that the R&D timeline may extend beyond the standard 4-week period depending on the complexity of the formulation and the availability of required active ingredients.
   2.4 Supplier Lead Time & Force Majeure: Any delays resulting from the lead times of raw material suppliers are beyond the Manufacturer’s direct control. Consequently, such delays shall not be considered the fault or negligence of the Manufacturer. The Brand Owner agrees that the Manufacturer is not liable for project extensions caused by supplier stock-outs or shipping delays from third-party ingredient providers.
   2.5 Sample Deliverables: Each batch typically consists of 5 to 10 pieces.
3. RAW MATERIALS AND SOURCING
   3.1 Manufacturer Sourcing: The Manufacturer is responsible for sourcing the necessary raw materials and active ingredients to meet the Brand Owner’s desired effects.
   3.2 Client-Supplied Ingredients: Should the Brand Owner choose to provide their own ingredients for the formulation, they are strictly required to submit the following documentation for each material: Technical Data Sheet (TDS), Certificate of Analysis (COA), Safety Data Sheet (SDS)
   3.3 Non-Negotiable Policy: The submission of the TDS, COA, and SDS for client-supplied ingredients is non-negotiable. The Manufacturer reserves the right to refuse any ingredient that is not accompanied by this complete documentation to ensure product safety and regulatory compliance.
   3.4 Timeline Constraints: Both parties acknowledge that the total development timeline is strictly contingent upon the market availability of specialized active ingredients requested by the Brand Owner.
4. STABILITY TESTING AND LIMITATION OF LIABILITY
   4.1 Testing Requirement: Once formulation is complete, the product must undergo rigorous stability testing to ensure quality, safety, and efficacy under various conditions.
   4.2 Timeline: Full stability testing to determine shelf life and long-term performance takes approximately 3 to 6 months to complete.
   4.3 Assumption of Risk: The Brand Owner acknowledges the risk of proceeding with a product launch prior to the completion of the full stability testing period.
   4.4 Waiver of Liability: The Manufacturer shall not be held liable for any issues—including but not limited to separation, discoloration, or performance changes—arising from the decision to launch the product before testing is finalized.
   4.5 Reformulation Commitment: If the Manufacturer’s R&D team identifies instability during the testing period, the Manufacturer will take immediate action to provide a revised formulation.
5. INTELLECTUAL PROPERTY AND EXCLUSIVITY
   5.1 Manufacturer Ownership: The chemical formulations, manufacturing processes, technical data, and trade secrets developed under this Agreement remain the sole and exclusive intellectual property of the Manufacturer for “in-house use” only.
   5.2 Limited Ownership for Brand Owner: The Brand Owner is granted Limited Ownership of the specific final product concept and “Ingredients List” for marketing and product registration (FDA CPN). This does not include rights to the formulation recipe or third-party manufacturing.
   5.3 Manufacturing Exclusivity: The approved formulation must be exclusively manufactured by OLC Cosmetics Manufacturing. Transferring the formulation to a third party is prohibited.
   5.4 Brand Exclusivity: The Manufacturer shall keep the specific branding and formulation exclusive to the Brand Owner.
6. CONFIDENTIALITY
   6.1. Mutual Non-Disclosure: Both parties agree to keep all branding, ingredient lists, and formulation processes strictly confidential. This information shall be used solely to fulfill this Agreement and will not be shared with unauthorized persons.
   6.2. Third-Party Consent: The Manufacturer shall not disclose any proprietary information related to the Brand Owner’s project to third parties (such as external vendors or other clients) without prior written consent. Notwithstanding the foregoing, the Manufacturer may disclose such information without prior consent only to the Department of Health – Food and Drug Administration (DOH-FDA) or as required by a court of competent jurisdiction.